Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147953 | 1.00 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EKMT2ALMNA | |
| SCHEMBL1147949 | 1.00 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EKMT2ALMNA | |
| SCHEMBL4792023 | 0.91 | MTNR1A (0.43) | MTNR1AMTNR1BKDM4EKMT2ASLC22A12 | |
| SCHEMBL3252542 | 0.91 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4ELMNASLC22A12 | |
| SCHEMBL3250707 | 0.91 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4ELMNASLC22A12 | |
| SCHEMBL3252537 | 0.91 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4ELMNASLC22A12 | |
| SCHEMBL3686476 | 0.88 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4ELMNASLC22A12 | |
| SCHEMBL3256511 | 0.87 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4EKMT2ALMNA | |
| SCHEMBL3256516 | 0.87 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4EKMT2ALMNA | |
| SCHEMBL3256520 | 0.87 | MTNR1A (0.51) | MTNR1AMTNR1BKDM4EKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888359-B2 | Cyclohexyl or piperidinyl carboxamide antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-02-15 | — | — | US | disclosed |
| EP-2001478-B1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | CBR3, RXFP4, ODC1 | MTNR1A 1051/4885MTNR1B 1457/4885KDM4E 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.